Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review.

Schizophrenia bulletin open Pub Date : 2021-11-28 eCollection Date: 2022-01-01 DOI:10.1093/schizbullopen/sgab053

Garrison J B Dyck, Zaid H Maayah, Dean T Eurich, Jason R B Dyck

{"title":"Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review.","authors":"Garrison J B Dyck, Zaid H Maayah, Dean T Eurich, Jason R B Dyck","doi":"10.1093/schizbullopen/sgab053","DOIUrl":null,"url":null,"abstract":"<p><p>Research suggests that cannabis-derived delta-9-tetrahydrocannabinol can be linked to the worsening of psychosis and/or other symptoms of schizophrenia. However, studies have shown that another major cannabinoid found in cannabis, cannabidiol (CBD), may be a potential alternative or adjunctive treatment for psychosis and schizophrenia. As such, herein we review the relevant literature relating to the safety and efficacy of CBD treatment in patients with schizophrenia, including the effects of CBD in treating the positive, negative, and cognitive symptoms of the disorder, as well as the molecular mechanisms by which CBD can reduce schizophrenic symptoms. The potential utility of CBD for mitigating cannabis cravings and cannabis withdrawal in this patient population will also be reviewed. Lastly, the dosing, method of drug delivery, length of treatment, and adverse effects of CBD in patients with schizophrenia are discussed. Thus, the goal of this narrative review is to help clinicians and researchers better understand the risks and benefits of this potential therapy for this patient population.</p>","PeriodicalId":94380,"journal":{"name":"Schizophrenia bulletin open","volume":"3 1","pages":"sgab053"},"PeriodicalIF":0.0000,"publicationDate":"2021-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11205871/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Schizophrenia bulletin open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/schizbullopen/sgab053","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Research suggests that cannabis-derived delta-9-tetrahydrocannabinol can be linked to the worsening of psychosis and/or other symptoms of schizophrenia. However, studies have shown that another major cannabinoid found in cannabis, cannabidiol (CBD), may be a potential alternative or adjunctive treatment for psychosis and schizophrenia. As such, herein we review the relevant literature relating to the safety and efficacy of CBD treatment in patients with schizophrenia, including the effects of CBD in treating the positive, negative, and cognitive symptoms of the disorder, as well as the molecular mechanisms by which CBD can reduce schizophrenic symptoms. The potential utility of CBD for mitigating cannabis cravings and cannabis withdrawal in this patient population will also be reviewed. Lastly, the dosing, method of drug delivery, length of treatment, and adverse effects of CBD in patients with schizophrenia are discussed. Thus, the goal of this narrative review is to help clinicians and researchers better understand the risks and benefits of this potential therapy for this patient population.

查看原文本刊更多论文

了解大麻二酚对精神分裂症患者的潜在益处：叙述性综述。

研究表明，从大麻中提取的δ-9-四氢大麻酚可能与精神病和/或精神分裂症其他症状的恶化有关。不过，研究表明，大麻中的另一种主要大麻素大麻二酚（CBD）可能是治疗精神病和精神分裂症的潜在替代品或辅助疗法。因此，我们在此回顾了有关大麻二酚治疗精神分裂症患者的安全性和有效性的相关文献，包括大麻二酚治疗精神分裂症的阳性、阴性和认知症状的效果，以及大麻二酚减轻精神分裂症症状的分子机制。此外，还将综述 CBD 在减轻这类患者对大麻的渴望和大麻戒断方面的潜在作用。最后，还将讨论精神分裂症患者服用 CBD 的剂量、给药方法、疗程和不良反应。因此，本综述的目的是帮助临床医生和研究人员更好地了解这种潜在疗法对这一患者群体的风险和益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Schizophrenia bulletin open

CiteScore

2.90

自引率

0.00%

发文量